Swiss National Bank Sells 2,900 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Swiss National Bank decreased its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 16.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,400 shares of the company’s stock after selling 2,900 shares during the period. Swiss National Bank’s holdings in Dianthus Therapeutics were worth $314,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. State Street Corp grew its holdings in Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after buying an additional 413,425 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Dianthus Therapeutics by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock valued at $25,936,000 after acquiring an additional 273,670 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Dianthus Therapeutics by 151.3% in the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after purchasing an additional 263,500 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after purchasing an additional 97,362 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new stake in Dianthus Therapeutics during the third quarter valued at $1,473,000. 47.53% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

DNTH has been the subject of a number of recent research reports. Guggenheim reissued a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. TD Cowen assumed coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $54.33.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $19.99 on Monday. Dianthus Therapeutics, Inc. has a fifty-two week low of $17.50 and a fifty-two week high of $32.27. The company has a market cap of $642.18 million, a price-to-earnings ratio of -8.00 and a beta of 1.82. The business’s 50 day moving average price is $21.91 and its 200-day moving average price is $24.24.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Sell-side analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.